HRP20170115T1 - Sastav tumoru-pridruženih peptida i povezanog cjepiva protiv karcinoma za liječenje glioblastoma (gbm-a) i drugih karcinoma - Google Patents

Sastav tumoru-pridruženih peptida i povezanog cjepiva protiv karcinoma za liječenje glioblastoma (gbm-a) i drugih karcinoma Download PDF

Info

Publication number: HRP20170115T1
Authority: HR; Croatia
Prior art keywords: cancer; pharmaceutical composition; composition according; peptide; seq
Prior art date: 2008-10-01

Application number

HRP20170115TT

Other languages

English (en)

Croatian (hr)

Inventor

Oliver Schoor

Norbert Hilf

Toni Weinschenk

Claudia Trautwein

Steffen Walter

Harpreet Singh

Original Assignee

Immatics Biotechnologies Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-01

Filing date

2009-09-28

Publication date

2017-03-24

2009-09-28 Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh

2017-03-24 Publication of HRP20170115T1 publication Critical patent/HRP20170115T1/hr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Mycology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Developmental Biology & Embryology (AREA)
Toxicology (AREA)
Heart & Thoracic Surgery (AREA)
Anesthesiology (AREA)
Vascular Medicine (AREA)

HRP20170115TT 2008-10-01 2009-09-28 Sastav tumoru-pridruženih peptida i povezanog cjepiva protiv karcinoma za liječenje glioblastoma (gbm-a) i drugih karcinoma HRP20170115T1 (hr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP20080017305 EP2172211B1 (en)	2008-10-01	2008-10-01	Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
US10597008P	2008-10-16	2008-10-16
PCT/EP2009/006979 WO2010037513A1 (en)	2008-10-01	2009-09-28	Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers
EP09778749.3A EP2331118B1 (en)	2008-10-01	2009-09-28	Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers

Publications (1)

Publication Number	Publication Date
HRP20170115T1 true HRP20170115T1 (hr)	2017-03-24

Family

ID=40342382

Family Applications (12)

Application Number	Title	Priority Date	Filing Date
HRP20170115TT HRP20170115T1 (hr)	2008-10-01	2009-09-28	Sastav tumoru-pridruženih peptida i povezanog cjepiva protiv karcinoma za liječenje glioblastoma (gbm-a) i drugih karcinoma
HRP20160915TT HRP20160915T1 (hr)	2008-10-01	2009-09-28	Nova imunoterapija protiv nekoliko tumora uključujući neuronske tumore i tumore mozga
HRP20201025TT HRP20201025T8 (hr)	2008-10-01	2009-09-28	Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20150223TT HRP20150223T8 (hr)	2008-10-01	2015-02-26	Sastav tumoru-pridruženih peptida i povezanog cjepiva protiv karcinoma za lijeäśenje glioblastoma (gbm-a) i drugih karcinoma
HRP20161504TT HRP20161504T1 (hr)	2008-10-01	2016-11-15	Nova imunoterapija protiv nekoliko tumora uključujući neuronske tumore i tumore mozga
HRP20182151TT HRP20182151T1 (hr)	2008-10-01	2018-12-18	Inovativna imunoterapija protiv nekoliko tumora uključujući neuronske i moždane tumore
HRP20190202TT HRP20190202T1 (hr)	2008-10-01	2019-01-31	Nova imunoterapija protiv nekoliko tumora uključujući tumore živčanih stanica i tumore mozga
HRP20200110TT HRP20200110T1 (hr)	2008-10-01	2020-01-23	Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20200722TT HRP20200722T1 (hr)	2008-10-01	2020-05-05	Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20200988TT HRP20200988T1 (hr)	2008-10-01	2020-06-19	Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20201015TT HRP20201015T8 (hr)	2008-10-01	2020-06-26	Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20201228TT HRP20201228T1 (hr)	2008-10-01	2020-08-06	Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga

Family Applications After (11)

Application Number	Title	Priority Date	Filing Date
HRP20160915TT HRP20160915T1 (hr)	2008-10-01	2009-09-28	Nova imunoterapija protiv nekoliko tumora uključujući neuronske tumore i tumore mozga
HRP20201025TT HRP20201025T8 (hr)	2008-10-01	2009-09-28	Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20150223TT HRP20150223T8 (hr)	2008-10-01	2015-02-26	Sastav tumoru-pridruženih peptida i povezanog cjepiva protiv karcinoma za lijeäśenje glioblastoma (gbm-a) i drugih karcinoma
HRP20161504TT HRP20161504T1 (hr)	2008-10-01	2016-11-15	Nova imunoterapija protiv nekoliko tumora uključujući neuronske tumore i tumore mozga
HRP20182151TT HRP20182151T1 (hr)	2008-10-01	2018-12-18	Inovativna imunoterapija protiv nekoliko tumora uključujući neuronske i moždane tumore
HRP20190202TT HRP20190202T1 (hr)	2008-10-01	2019-01-31	Nova imunoterapija protiv nekoliko tumora uključujući tumore živčanih stanica i tumore mozga
HRP20200110TT HRP20200110T1 (hr)	2008-10-01	2020-01-23	Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20200722TT HRP20200722T1 (hr)	2008-10-01	2020-05-05	Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20200988TT HRP20200988T1 (hr)	2008-10-01	2020-06-19	Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20201015TT HRP20201015T8 (hr)	2008-10-01	2020-06-26	Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20201228TT HRP20201228T1 (hr)	2008-10-01	2020-08-06	Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga

Country Status (24)

Country	Link
US (20)	US8318677B2 (2)
EP (12)	EP2172211B1 (2)
JP (10)	JP5753783B2 (2)
KR (6)	KR102392070B1 (2)
CN (3)	CN102170901B (2)
AU (2)	AU2009300087B2 (2)
BR (2)	BRPI0920791B8 (2)
CA (9)	CA2936920C (2)
CY (11)	CY1116302T1 (2)
DK (12)	DK2172211T3 (2)
EA (3)	EA032437B1 (2)
ES (12)	ES2536465T3 (2)
HR (12)	HRP20170115T1 (2)
HU (11)	HUE031030T2 (2)
LT (10)	LT2172212T (2)
MX (3)	MX2011003540A (2)
NZ (4)	NZ591855A (2)
PL (12)	PL2172211T3 (2)
PT (12)	PT2172211E (2)
RS (12)	RS53782B1 (2)
SI (12)	SI2172211T1 (2)
TR (2)	TR201900852T4 (2)
UA (3)	UA125277C2 (2)
WO (2)	WO2010037513A1 (2)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006023598A2 (en)	2004-08-19	2006-03-02	University Of Maryland, Baltimore	Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
US7612162B2 (en)	2004-09-21	2009-11-03	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
HRP20150820T1 (xx) *	2007-07-27	2015-09-11	Immatics Biotechnologies Gmbh	Nova imunoterapija protiv neuronskih tumora i tumora mozga
EP2113253B1 (en) *	2008-04-30	2010-03-31	Immatics Biotechnologies GmbH	Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
ES2532896T5 (es)	2008-05-14	2018-03-20	Immatics Biotechnologies Gmbh	Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
RS53782B1 (sr) *	2008-10-01	2015-06-30	Immatics Biotechnologies Gmbh	Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
TW201124530A (en) *	2009-12-01	2011-07-16	Oncotherapy Science Inc	IMP-3 oligopeptides and vaccines including the same
SE535982C2 (sv) *	2009-12-15	2013-03-19	Theravac Pharmaceuticals Ab	Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
GB201004551D0 (en) *	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2015200751B2 (en) *	2010-03-19	2016-11-10	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
CA2809362C (en) *	2010-08-24	2020-03-10	University Of Pittsburgh - Of The Commonwealth System Of Higher Educatn	Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US20140017266A1 (en) *	2010-12-03	2014-01-16	The Government Of The United States, As Represented By The Secretary Of Hhs, Nih	Anti-podoplanin antibodies and methods of use
CA2821582A1 (en) *	2010-12-14	2012-06-21	Immatics Biotechnologies Gmbh	Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
US20140154269A1 (en) *	2011-04-26	2014-06-05	The Methodist Hospital Research Institute	Targeted nanovectors and their use for treatment of brain tumors
AU2012308302A1 (en) *	2011-09-14	2014-03-20	Northwestern University	Nanoconjugates able to cross the blood-brain barrier
GB201120779D0 (en)	2011-12-02	2012-01-11	Immodulon Therapeutics Ltd	Cancer therapy
EP2804602B1 (en)	2012-01-20	2024-12-04	Del Mar Pharmaceuticals	Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
US10704021B2 (en)	2012-03-15	2020-07-07	Flodesign Sonics, Inc.	Acoustic perfusion devices
CN103372217B (zh) *	2012-04-28	2014-12-10	中国科学院深圳先进技术研究院	聚合物纳米载体制剂及其制备方法和应用
CA3183703A1 (en)	2012-05-16	2013-11-21	Stemline Therapeutics, Inc.	Cancer stem cell targeted cancer vaccines
CN112587671A (zh) *	2012-07-18	2021-04-02	博笛生物科技有限公司	癌症的靶向免疫治疗
TWI636065B (zh) *	2013-08-05	2018-09-21	伊瑪提克斯生物科技有限公司	新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
ES3009756T3 (en)	2013-08-05	2025-03-31	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumors, such as lung cancer including nsclc
MX2019013161A (es) *	2013-11-04	2020-02-03	Immatics Biotechnologies Gmbh	Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
GB201319446D0 (en)	2013-11-04	2013-12-18	Immatics Biotechnologies Gmbh	Personalized immunotherapy against several neuronal and brain tumors
CN104698059B (zh) *	2013-12-04	2017-07-21	苏州中赢医疗科技有限公司	一种脑胶质瘤肿瘤标志物及其应用
GB201322725D0 (en)	2013-12-20	2014-02-05	Immodulon Therapeutics Ltd	Cancer therapy
WO2015105955A1 (en)	2014-01-08	2015-07-16	Flodesign Sonics, Inc.	Acoustophoresis device with dual acoustophoretic chamber
KR101503341B1 (ko)	2014-03-12	2015-03-18	국립암센터	자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
PL3134432T3 (pl)	2014-04-25	2020-10-19	Bluebird Bio, Inc.	Promotor mnd chimeryczne receptory antygenowe
HUE049514T2 (hu)	2014-04-25	2020-09-28	Bluebird Bio Inc	Javított eljárások adoptív sejtterápiák kialakítására
JP6613526B2 (ja) *	2014-05-28	2019-12-04	学校法人東京女子医科大学	膠芽腫の予測方法
JP2015227292A (ja) *	2014-05-30	2015-12-17	国立大学法人高知大学	膵がん細胞浸潤転移抑制ワクチン
SI3151672T1 (sl)	2014-06-06	2021-03-31	Bluebird Bio, Inc.	Izboljšani T-celični sestavki
JP6366379B2 (ja) *	2014-06-20	2018-08-01	キヤノン株式会社	被検体情報取得装置
ES2878449T3 (es)	2014-07-24	2021-11-18	2Seventy Bio Inc	Receptores antigénicos quiméricos de BCMA
JP6474893B2 (ja) *	2014-11-06	2019-02-27	オーエスイー・イミュノセラピューティクス	脳転移の処置のための治療用マルチペプチドｔ特異的免疫療法
HRP20191873T1 (hr)	2014-12-12	2020-01-24	Bluebird Bio, Inc.	Kimerni antigenski receptori
GB201501017D0 (en) *	2014-12-23	2015-03-04	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA49156A (fr)	2014-12-23	2020-03-25	Immatics Biotechnologies Gmbh	Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
GB201423361D0 (en) *	2014-12-30	2015-02-11	Immatics Biotechnologies Gmbh	Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
MY190083A (en)	2015-03-17	2022-03-25	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201505585D0 (en)	2015-03-31	2015-05-13	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
US11377651B2 (en)	2016-10-19	2022-07-05	Flodesign Sonics, Inc.	Cell therapy processes utilizing acoustophoresis
US11708572B2 (en)	2015-04-29	2023-07-25	Flodesign Sonics, Inc.	Acoustic cell separation techniques and processes
GB201507719D0 (en) *	2015-05-06	2015-06-17	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
IL308202A (en) *	2015-05-06	2024-01-01	Immatics Biotechnologies Gmbh	Novel peptides and combination of oeptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en)	2015-06-08	2017-02-03	Applied Immune Tech Ltd	T cell receptor like antibodies having fine specificity.
EP3307307A4 (en)	2015-06-09	2019-05-01	The Board of Regents of the University of Oklahoma	COMPOSITIONS AND TREATMENTS FOR HAEMOPHILUS INFLUENZAE
RU2733033C2 (ru)	2015-06-24	2020-09-28	Иммодьюлон Терапьютикс Лимитед	Ингибитор контрольных точек и целые клетки микобактерий для применения в терапии рака
MA54884A (fr)	2015-07-01	2022-01-12	Immatics Biotechnologies Gmbh	Neuartige peptide und kombination aus peptiden zur verwendung in der immuntherapie gegen ovarialkarzinom und andere karzinome
GB201511546D0 (en)	2015-07-01	2015-08-12	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CR20230563A (es) *	2015-07-06	2024-01-22	Immatics Biotechnologies Gmbh	NUEVOS PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS PARA USAR EN INMUNOTERAPIA CONTRA EL CÁNCER ESOFÁGICO Y OTROS CÁNCERES (Divisional Exp. 2017-0579)
MY189596A (en) *	2015-07-15	2022-02-18	Immatics Biotechnologies Gmbh	A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) *	2015-08-05	2015-09-23	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
TWI782434B (zh)	2015-08-28	2022-11-01	德商英麥提克生物技術股份有限公司	用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
GB201515321D0 (en)	2015-08-28	2015-10-14	Immatics Biotechnologies Gmbh	Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
EP3344276B1 (en)	2015-09-03	2020-04-22	The Board of Regents of the University of Oklahoma	Peptide inhibitors of clostridium difficile tcdb toxin
CN108289909A (zh)	2015-10-19	2018-07-17	巴尔的摩马里兰大学	用于产生工程改造的人原代血液树突细胞系的方法
US11479755B2 (en)	2015-12-07	2022-10-25	2Seventy Bio, Inc.	T cell compositions
GB201521746D0 (en) *	2015-12-10	2016-01-27	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
PE20230343A1 (es) *	2015-12-11	2023-03-01	Immatics Biotechnologies Gmbh	Peptidos que estimulan respuestas inmunitarias antitumorales
ES2970865T3 (es)	2015-12-16	2024-05-31	Gritstone Bio Inc	Identificación, fabricación y uso de neoantígenos
WO2017123996A1 (en)	2016-01-15	2017-07-20	City Of Hope	Targeting glioblastoma stem cells through the tlx-tet3 axis
GB201603568D0 (en) *	2016-03-01	2016-04-13	Immatics Biotechnologies Gmbh	Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en)	2016-03-08	2016-04-20	Immatics Biotechnologies Gmbh	Uterine cancer treatments
CN109620949A (zh) *	2016-03-13	2019-04-16	曹帅	一种用于治疗骨癌的药物组合物
GB201604494D0 (en)	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
GB201604490D0 (en) *	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Peptides combination of peptides for use in immunotherapy against cancers
NZ746387A (en)	2016-03-16	2022-08-26	Immatics Biotechnologies Gmbh	Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
CN109071605A (zh) *	2016-04-06	2018-12-21	伊玛提克斯生物技术有限公司	用于aml和其他癌症免疫治疗的新型肽和肽组合物
US11214789B2 (en)	2016-05-03	2022-01-04	Flodesign Sonics, Inc.	Concentration and washing of particles with acoustics
WO2017194170A1 (en) *	2016-05-13	2017-11-16	Biontech Rna Pharmaceuticals Gmbh	Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR101881300B1 (ko)	2016-06-30	2018-07-25	영남대학교 산학협력단	아조피라졸 화합물 및 은 촉매 반응을 이용한 이의 신규한 합성방법
SI3518948T1 (sl) *	2016-10-03	2023-09-29	Ottawa Hospital Research Institute	Kompozicije in metode za povečanje rasti, širjenja ter onkolitične in imunoterapevtske učinkovitosti onkolitičnih RNA-virusov
WO2018085690A1 (en)	2016-11-04	2018-05-11	Bluebird Bio, Inc.	Anti-bcma car t cell compositions
KR102379955B1 (ko)	2016-12-08	2022-03-29	이매틱스 바이오테크놀로지스 게엠베하	짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de)	2016-12-08	2018-06-14	Immatics Biotechnologies Gmbh	T-Zellrezeptoren mit verbesserter Bindung
ES2973548T3 (es)	2016-12-22	2024-06-20	Cue Biopharma Inc	Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
CN112210010B (zh)	2017-01-06	2023-12-05	优特力克斯有限公司	抗-人4-1bb抗体及其应用
GB201702863D0 (en) *	2017-02-22	2017-04-05	Evox Therapeutics Ltd	Improved loading of EVs with therapeutic proteins
WO2018160498A1 (en) *	2017-02-28	2018-09-07	Lyten, Inc.	Mixed allotrope particulate carbon films and carbon fiber mats
EP3634449A4 (en) *	2017-05-08	2021-03-17	Gritstone Oncology, Inc.	ALPHAVIRUS NEOANTIGEN VECTORS
CN107058596A (zh) *	2017-06-19	2017-08-18	上海市第十人民医院	一种与恶性胶质瘤诊断相关的标志物及其应用
CN107034305A (zh) *	2017-06-19	2017-08-11	上海市第十人民医院	恶性胶质瘤的一种诊断标志物
EP4576103A3 (en)	2017-10-10	2025-08-27	Gritstone bio, Inc.	Neoantigen identification using hotspots
CN111630602A (zh)	2017-11-22	2020-09-04	磨石肿瘤生物技术公司	减少新抗原的接合表位呈递
EP3724327A4 (en) *	2017-12-14	2022-01-12	EZY Biotech LLC	SUBJECT-SPECIFIC TUMOR-INHIBITING CELLS AND THEIR USE
KR102439221B1 (ko)	2017-12-14	2022-09-01	프로디자인 소닉스, 인크.	음향 트랜스듀서 구동기 및 제어기
HRP20230007T1 (hr) *	2018-04-11	2023-03-03	Enterome S.A.	Antigenski peptidi, namijenjeni sprječavanju i liječenju raka
CN108715832B (zh) *	2018-06-01	2020-11-10	段海峰	一种抑制肿瘤生长的间充质干细胞及制备方法和应用
WO2020014471A1 (en)	2018-07-11	2020-01-16	The Brigham And Women's Hospital, Inc.	Methods and compositions for delivery of agents across the blood-brain barrier
WO2020110154A1 (en) *	2018-11-30	2020-06-04	Bharat Biotech International Limited	A chimeric therapeutic vaccine
RU2706554C1 (ru) *	2018-12-13	2019-11-19	Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ	Способ создания противоинфекционной иммунологической защиты к Salmonella typhimurium и Listeria monocytogenes с помощью трансгенеза Т-лимфоцитов
CN109796536B (zh) *	2019-02-22	2021-09-17	上海尚泰生物技术有限公司	一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法
BR112021018854A2 (pt)	2019-03-29	2021-11-30	Intervet Int Bv	Estabilização de bactérias mollicutes vivas em uma composição líquida
US12582726B1 (en)	2019-04-05	2026-03-24	Earli Inc.	Synthetic cancer-specific promoters
JP2022527629A (ja)	2019-04-05	2022-06-02	アーリー・インコーポレイテッド	合成バイオマーカーのための改良された方法及び組成物
AU2020284538B2 (en)	2019-05-28	2022-03-24	PAIGE.AI, Inc.	Systems and methods for processing images to prepare slides for processed images for digital pathology
MX2021014525A (es)	2019-05-30	2022-03-17	Gritstone Bio Inc	Adenovirus modificados.
CN110579457B (zh) *	2019-09-20	2021-11-02	郑州大学第一附属医院	波形蛋白特异响应性荧光探针及其制备方法和应用
CN112824427B (zh) *	2019-11-18	2022-06-24	杨小骏	一种抑制胶质瘤的短肽及其应用
CN115279400B (zh) *	2020-01-10	2026-04-28	布里格姆妇女医院	用于跨血脑屏障递送免疫治疗剂以治疗脑癌的方法和组合物
CA3170412A1 (en) *	2020-02-24	2021-09-02	The Regents Of The University Of California	Use of brain-specific antigens to home, block and deliver cell-based treatments to the brain
CN113318225B (zh) *	2020-02-28	2024-01-19	无锡派列博生物医药科技有限公司	肿瘤免疫增强剂及其制法和应用
CN111333698B (zh) *	2020-03-18	2021-11-23	北京鼎成肽源生物技术有限公司	一种乳腺癌靶标抗原组合、乳腺癌靶标抗原组合刺激培养的ctl细胞及其应用
KR20230006821A (ko) *	2020-03-31	2023-01-11	워킹 피쉬 테라퓨틱스	변형 b 세포 및 이의 사용 방법
EP4127188A4 (en)	2020-03-31	2024-08-21	Walking Fish Therapeutics	MODIFIED B CELLS AND METHODS OF USE THEREOF
WO2021231376A2 (en)	2020-05-12	2021-11-18	Cue Biopharma, Inc.	Multimeric t-cell modulatory polypeptides and methods of use thereof
US20230279424A1 (en) *	2020-05-26	2023-09-07	University Health Network	Combination cytokines for methods and compositions for treating cancer
CN116438308A (zh)	2020-08-06	2023-07-14	磨石生物公司	多表位疫苗盒
KR102711471B1 (ko)	2020-08-14	2024-09-30	서울대학교산학협력단	B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물
CA3190707A1 (en) *	2020-08-28	2022-03-03	Torigen Pharmaceuticals, Inc.	Immune memory enhanced preparations and uses thereof
CN116710115A (zh)	2020-11-20	2023-09-05	思维疗法股份有限公司	用于优化的肽疫苗的组合物和方法
US11421015B2 (en)	2020-12-07	2022-08-23	Think Therapeutics, Inc.	Method of compact peptide vaccines using residue optimization
US11058751B1 (en)	2020-11-20	2021-07-13	Think Therapeutics, Inc.	Compositions for optimized RAS peptide vaccines
WO2022192457A1 (en) *	2021-03-09	2022-09-15	Bostongene Corporation	Predicting response to treatments in patients with clear cell renal cell carcinoma
US11464842B1 (en)	2021-04-28	2022-10-11	Think Therapeutics, Inc.	Compositions and method for optimized peptide vaccines using residue optimization
US20250235517A1 (en) *	2022-03-30	2025-07-24	Iogenetics, Llc	Tumor-associated antigens in brain tumors
PL441229A1 (pl) *	2022-05-19	2023-11-20	Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk	Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych
KR102907303B1 (ko)	2024-12-23	2025-12-31	전남대학교산학협력단	다중 분기 잠재 확산 모델 기반 초음파 유도 조직 검사 바늘의 경로 및 위치 실시간 검출 장치, 방법
CN120272531B (zh) *	2025-06-10	2025-08-19	鼐济医药科技(杭州)有限公司	一种基于aav介导免疫微环境的脑胶质瘤动物模型构建方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4440859A (en)	1977-05-27	1984-04-03	The Regents Of The University Of California	Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
LU88258I2 (2)	1978-12-22	1994-02-03
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en)	1980-02-22	1982-08-03	Scripps Clinic & Research Foundation	Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en)	1981-09-25	1987-07-07	Genentech, Inc.	Hybrid human leukocyte interferons
US4766075A (en)	1982-07-14	1988-08-23	Genentech, Inc.	Human tissue plasminogen activator
US4582800A (en)	1982-07-12	1986-04-15	Hoffmann-La Roche Inc.	Novel vectors and method for controlling interferon expression
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4757006A (en)	1983-10-28	1988-07-12	Genetics Institute, Inc.	Human factor VIII:C gene and recombinant methods for production
US4677063A (en)	1985-05-02	1987-06-30	Cetus Corporation	Human tumor necrosis factor
US4810648A (en)	1986-01-08	1989-03-07	Rhone Poulenc Agrochimie	Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en)	1986-06-27	1990-01-30	The Administrators Of The Tulane Educational Fund	Method for synthesizing a peptide containing a non-peptide bond
US5338839A (en) *	1988-04-12	1994-08-16	Massachusetts Institute Of Technology	DNA encoding nestin protein
KR100235089B1 (en)	1992-05-14	1999-12-15	Mitsui Chemicals Inc	Ptp or blister packaging articles and packaging material therefor
GB2267257A (en)	1992-05-14	1993-12-01	Ford Motor Co	A vehicle load compartment liner.
ATE183513T1 (de)	1993-06-03	1999-09-15	Therapeutic Antibodies Inc	Herstellung von antikörperfragmenten
AUPM322393A0 (en)	1993-12-24	1994-01-27	Austin Research Institute, The	Mucin carbohydrate compounds and their use in immunotherapy
CA2243235C (en)	1996-01-17	2010-08-10	Imperial College Innovations Limited	Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en)	1996-03-11	1998-12-15	Duke University	Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
IL120561A0 (en) *	1996-04-24	1997-07-13	Akzo Nobel Nv	Peptides suitable for use in immunosuppressive therapy
WO1998003197A1 (en) *	1996-07-22	1998-01-29	The Rockefeller University	Env-glycoprotein vaccine for protection of htlv-i and -ii infection
WO1998031797A1 (en)	1997-01-15	1998-07-23	Zymogenetics, Inc.	Zppar6, human tailless nuclear hormone receptor (tlx receptor)
WO1998036062A1 (en) *	1997-02-13	1998-08-20	Smithkline Beecham Plc	Neural cell adhesion molecule splicing variants
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6682928B2 (en) *	1997-12-02	2004-01-27	Medarex, Inc.	Cells expressing anti-Fc receptor binding components
US7258860B2 (en) *	1998-03-18	2007-08-21	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
AU3762699A (en) *	1998-04-27	1999-11-16	Pacific Northwest Cancer Foundation	(nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
US6960651B2 (en) *	1999-06-29	2005-11-01	Millennium Pharmaceuticals, Inc.	TANGO 332 polypeptides
WO2001055301A2 (en) *	2000-01-31	2001-08-02	Human Genome Sciences, Inc.	Nucleic acids, proteins, and antibodies
US20020132753A1 (en) *	2000-01-31	2002-09-19	Rosen Craig A.	Nucleic acids, proteins, and antibodies
US20040191260A1 (en)	2003-03-26	2004-09-30	Technion Research & Development Foundation Ltd.	Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
IL151860A0 (en)	2000-03-27	2003-04-10	Technion Res & Dev Foundation	Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
AU2001279581A1 (en) *	2000-09-06	2002-03-22	Friederike Muller	Medicament comprising a dna sequence, which codes for the rna-binding koc protein, and comprising a koc protein or dna sequence of the koc promoter
US7919467B2 (en) *	2000-12-04	2011-04-05	Immunotope, Inc.	Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2002046416A2 (en) *	2000-12-04	2002-06-13	Argonex Pharmaceuticals	Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1379879A2 (en) *	2000-12-08	2004-01-14	Oxford GlycoSciences (UK) Limited	Diagnosis and treatment of alzheimer's disease
WO2002074237A2 (en) *	2001-03-19	2002-09-26	Corixa Corporation	Compositions and methods for the therapy and diagnosis of kidney cancer
CA2364106A1 (fr) *	2001-11-30	2003-05-30	Christopher Gillberg	Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques
US6589642B1 (en)	2001-12-21	2003-07-08	Kloeckner Pentaplast Of America, Inc.	Three part high moisture barrier for packages
US7892559B2 (en)	2002-01-30	2011-02-22	Survac Aps	Survivin-derived peptides and use thereof
US6992176B2 (en) *	2002-02-13	2006-01-31	Technion Research & Development Foundation Ltd.	Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en)	2002-02-20	2003-09-09	Dyax Corporation	Mhc-peptide complex binding ligands
WO2004015390A2 (en) *	2002-08-09	2004-02-19	Applera Corporation	Lung cancer target proteins and use thereof
JP4721633B2 (ja) *	2002-10-11	2011-07-13	財団法人癌研究会	血小板凝集促進活性を有する物質
WO2004067029A1 (fr) *	2002-12-27	2004-08-12	Shenzhen Tsinghua Yuanxing Bio-Pharm Science & Technology Co., Ltd.	Procede de preparation d'un vaccin et vaccins antitumoraux
WO2004089300A2 (en)	2003-04-04	2004-10-21	Pharmacyclics, Inc.	Sapphyrins and uses thereof
US7273980B2 (en)	2004-01-13	2007-09-25	Wardle Scott A	Position and velocity transducer using a phonograph disc and turntable
EP1712620A4 (en) *	2004-01-23	2008-05-28	Greenpeptide Co Ltd	EGF (EPIDERMAL GROWTH FACTOR) RECEPTOR-ORGANIC PEPTIDE
DE102004026135A1 (de)	2004-05-25	2006-01-05	Immatics Biotechnologies Gmbh	An MHC-Moleküle bindende Tumor-assoziierte Peptide
US20080280317A1 (en) *	2004-08-27	2008-11-13	Northeastern University	Comprehensive Characterization Of Complex Proteins At Trace Levels
EP1642905B1 (en) *	2004-10-02	2009-01-21	Immatics Biotechnologies GmbH	Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
ES2534752T3 (es) *	2004-12-07	2015-04-27	Toray Industries, Inc.	Nuevo péptido antigénico contra el cáncer y utilización del mismo
KR100809410B1 (ko) *	2005-07-06	2008-03-05	주식회사 브레인가드	줄기세포 분화 유도용 조성물 및 그의 용도
EP1760089B1 (en) *	2005-09-05	2009-08-19	Immatics Biotechnologies GmbH	Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
SI1806358T1 (sl)	2005-09-05	2010-06-30	Immatics Biotechnologies Gmbh	S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule humanega levkocitnega antigena HLA razreda II
EP1938104A2 (en)	2005-10-17	2008-07-02	Institute for Systems Biology	Tissue-and serum-derived glycoproteins and methods of their use
US20070248628A1 (en) *	2005-12-06	2007-10-25	Keller Lorraine H	Immunogens in cancer stem cells
WO2007072494A1 (en)	2005-12-23	2007-06-28	Naik Praful Ramchandra	Metallized packaging blister container
WO2008035350A1 (en) *	2006-09-21	2008-03-27	Vaxil Biotherapeutics Ltd.	Antigen specific multi epitope vaccines
CA2700573C (en) *	2006-09-26	2016-11-22	Cedars-Sinai Medical Center	Cancer stem cell antigen vaccines and methods
EP2164859A4 (en) *	2007-03-06	2012-06-06	Iterative Therapeutics Inc	METHOD AND COMPOSITIONS WITH POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS
EP2280731A1 (en) *	2008-04-09	2011-02-09	Technion Research and Development Foundation, Ltd.	Anti human immunodeficiency antibodies and uses thereof
KR101184869B1 (ko)	2008-04-24	2012-09-20	이매틱스 바이오테크놀로지스 게엠베하	백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형
EP2113253B1 (en) *	2008-04-30	2010-03-31	Immatics Biotechnologies GmbH	Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
RS53782B1 (sr)	2008-10-01	2015-06-30	Immatics Biotechnologies Gmbh	Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
GB201004551D0 (en)	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201021289D0 (en)	2010-12-15	2011-01-26	Immatics Biotechnologies Gmbh	Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
CN106661126B (zh) *	2014-05-28	2021-12-10	诺诺公司	TAT-NR2B9c的氯盐
SG11201808629UA (en)	2016-04-21	2018-11-29	Immatics Biotechnologies Gmbh	Immunotherapy against melanoma and other cancers
CN111315769A (zh) *	2017-09-06	2020-06-19	加州理工学院	信号传导和抗原呈递双功能受体(sabr)

2008
- 2008-10-01 RS RS20150094A patent/RS53782B1/sr unknown
- 2008-10-01 PL PL08017305T patent/PL2172211T3/pl unknown
- 2008-10-01 EP EP20080017305 patent/EP2172211B1/en active Active
- 2008-10-01 SI SI200831373T patent/SI2172211T1/sl unknown
- 2008-10-01 ES ES08017305.7T patent/ES2536465T3/es active Active
- 2008-10-01 PT PT80173057T patent/PT2172211E/pt unknown
- 2008-10-01 DK DK08017305T patent/DK2172211T3/en active
- 2008-10-13 PL PL08017921T patent/PL2172212T3/pl unknown
- 2008-10-13 EP EP08017921.1A patent/EP2172212B1/en active Active
- 2008-10-13 PT PT80179211T patent/PT2172212T/pt unknown
- 2008-10-13 RS RS20161019A patent/RS55543B1/sr unknown
- 2008-10-13 DK DK08017921.1T patent/DK2172212T3/da active
- 2008-10-13 LT LTEP08017921.1T patent/LT2172212T/lt unknown
- 2008-10-13 HU HUE08017921A patent/HUE031030T2/en unknown
- 2008-10-13 SI SI200831695A patent/SI2172212T1/sl unknown
- 2008-10-13 ES ES08017921.1T patent/ES2607460T3/es active Active
2009
- 2009-09-28 LT LTEP16179163.7T patent/LT3106175T/lt unknown
- 2009-09-28 SI SI200932063T patent/SI3106175T1/sl unknown
- 2009-09-28 WO PCT/EP2009/006979 patent/WO2010037513A1/en not_active Ceased
- 2009-09-28 CA CA2936920A patent/CA2936920C/en active Active
- 2009-09-28 DK DK16179214.8T patent/DK3124043T3/da active
- 2009-09-28 SI SI200932056T patent/SI3124043T1/sl unknown
- 2009-09-28 HU HUE16179226A patent/HUE049364T2/hu unknown
- 2009-09-28 RS RS20200693A patent/RS60386B1/sr unknown
- 2009-09-28 ES ES16179226T patent/ES2802227T3/es active Active
- 2009-09-28 EA EA201401104A patent/EA032437B1/ru unknown
- 2009-09-28 LT LTEP16165070.0T patent/LT3069728T/lt unknown
- 2009-09-28 CN CN200980139420.5A patent/CN102170901B/zh not_active Expired - Fee Related
- 2009-09-28 LT LTEP09778749.3T patent/LT2331118T/lt unknown
- 2009-09-28 SI SI200932065T patent/SI3120868T1/sl unknown
- 2009-09-28 RS RS20200085A patent/RS60006B1/sr unknown
- 2009-09-28 SI SI200932034T patent/SI3132801T1/sl unknown
- 2009-09-28 CA CA2936869A patent/CA2936869C/en active Active
- 2009-09-28 MX MX2011003540A patent/MX2011003540A/es active IP Right Grant
- 2009-09-28 PL PL16179226T patent/PL3120870T3/pl unknown
- 2009-09-28 KR KR1020207019579A patent/KR102392070B1/ko not_active Expired - Fee Related
- 2009-09-28 ES ES16165070T patent/ES2710608T3/es active Active
- 2009-09-28 RS RS20200973A patent/RS60656B1/sr unknown
- 2009-09-28 HU HUE16179163A patent/HUE049367T2/hu unknown
- 2009-09-28 SI SI200932083T patent/SI3120869T1/sl unknown
- 2009-09-28 SI SI200932064T patent/SI3120870T1/sl unknown
- 2009-09-28 ES ES09778749.3T patent/ES2612466T3/es active Active
- 2009-09-28 EA EA201100587A patent/EA023378B1/ru unknown
- 2009-09-28 AU AU2009300087A patent/AU2009300087B2/en not_active Ceased
- 2009-09-28 HU HUE16179174A patent/HUE049366T2/hu unknown
- 2009-09-28 PT PT161791744T patent/PT3120868T/pt unknown
- 2009-09-28 SI SI200931902T patent/SI3111952T1/sl unknown
- 2009-09-28 PL PL16179192T patent/PL3120869T3/pl unknown
- 2009-09-28 PL PL16179174T patent/PL3120868T3/pl unknown
- 2009-09-28 ES ES16179163T patent/ES2802226T3/es active Active
- 2009-09-28 RS RS20200692A patent/RS60385B1/sr unknown
- 2009-09-28 CA CA2936868A patent/CA2936868C/en active Active
- 2009-09-28 NZ NZ591855A patent/NZ591855A/xx not_active IP Right Cessation
- 2009-09-28 EA EA201100586A patent/EA023013B1/ru unknown
- 2009-09-28 ES ES16179214T patent/ES2788129T3/es active Active
- 2009-09-28 BR BRPI0920791A patent/BRPI0920791B8/pt not_active IP Right Cessation
- 2009-09-28 LT LTEP16179214.8T patent/LT3124043T/lt unknown
- 2009-09-28 UA UAA201500916A patent/UA125277C2/uk unknown
- 2009-09-28 HU HUE16165070A patent/HUE041446T2/hu unknown
- 2009-09-28 SI SI200931573A patent/SI2331118T1/sl unknown
- 2009-09-28 EP EP16179241.1A patent/EP3111952B1/en active Active
- 2009-09-28 PT PT97787501T patent/PT2341927T/pt unknown
- 2009-09-28 KR KR1020117010003A patent/KR101756488B1/ko not_active Expired - Fee Related
- 2009-09-28 LT LTEP16179169.4T patent/LT3132801T/lt unknown
- 2009-09-28 PT PT97787493T patent/PT2331118T/pt unknown
- 2009-09-28 HR HRP20170115TT patent/HRP20170115T1/hr unknown
- 2009-09-28 PT PT161791694T patent/PT3132801T/pt unknown
- 2009-09-28 DK DK09778750.1T patent/DK2341927T3/en active
- 2009-09-28 EP EP16179214.8A patent/EP3124043B1/en active Active
- 2009-09-28 NZ NZ603016A patent/NZ603016A/en not_active IP Right Cessation
- 2009-09-28 AU AU2009300088A patent/AU2009300088B2/en not_active Ceased
- 2009-09-28 HU HUE09778749A patent/HUE030296T2/en unknown
- 2009-09-28 PL PL16179169T patent/PL3132801T3/pl unknown
- 2009-09-28 PL PL16179241T patent/PL3111952T3/pl unknown
- 2009-09-28 PL PL09778750.1T patent/PL2341927T3/pl unknown
- 2009-09-28 EP EP16179192.6A patent/EP3120869B1/en active Active
- 2009-09-28 EP EP09778749.3A patent/EP2331118B1/en active Active
- 2009-09-28 HU HUE09778750A patent/HUE029360T2/en unknown
- 2009-09-28 JP JP2011529471A patent/JP5753783B2/ja not_active Expired - Fee Related
- 2009-09-28 DK DK16165070.0T patent/DK3069728T3/en active
- 2009-09-28 HU HUE16179192A patent/HUE050428T2/hu unknown
- 2009-09-28 MX MX2012012047A patent/MX338294B/es unknown
- 2009-09-28 RS RS20200512A patent/RS60338B1/sr unknown
- 2009-09-28 EP EP16179226.2A patent/EP3120870B1/en active Active
- 2009-09-28 CN CN200980139419.2A patent/CN102170900B/zh active Active
- 2009-09-28 CA CA2936887A patent/CA2936887C/en active Active
- 2009-09-28 EP EP16165070.0A patent/EP3069728B1/en active Active
- 2009-09-28 LT LTEP16179226.2T patent/LT3120870T/lt unknown
- 2009-09-28 CN CN201610831523.XA patent/CN106986919A/zh active Pending
- 2009-09-28 RS RS20160553A patent/RS55043B1/sr unknown
- 2009-09-28 SI SI200931464A patent/SI2341927T1/sl unknown
- 2009-09-28 DK DK16179241.1T patent/DK3111952T3/en active
- 2009-09-28 PL PL09778749T patent/PL2331118T3/pl unknown
- 2009-09-28 ES ES16179169T patent/ES2770090T3/es active Active
- 2009-09-28 PT PT16179241T patent/PT3111952T/pt unknown
- 2009-09-28 EP EP16179174.4A patent/EP3120868B1/en active Active
- 2009-09-28 ES ES16179174T patent/ES2804723T3/es active Active
- 2009-09-28 HR HRP20160915TT patent/HRP20160915T1/hr unknown
- 2009-09-28 KR KR1020227013879A patent/KR20220058655A/ko not_active Ceased
- 2009-09-28 CA CA2936924A patent/CA2936924C/en active Active
- 2009-09-28 KR KR1020117010000A patent/KR101687840B1/ko not_active Expired - Fee Related
- 2009-09-28 CA CA2936982A patent/CA2936982C/en active Active
- 2009-09-28 PT PT16165070T patent/PT3069728T/pt unknown
- 2009-09-28 EP EP16179169.4A patent/EP3132801B1/en active Active
- 2009-09-28 SI SI200931921T patent/SI3069728T1/sl unknown
- 2009-09-28 RS RS20181585A patent/RS58229B1/sr unknown
- 2009-09-28 PL PL16179163T patent/PL3106175T3/pl unknown
- 2009-09-28 MX MX2011003539A patent/MX2011003539A/es active IP Right Grant
- 2009-09-28 RS RS20200691A patent/RS60381B1/sr unknown
- 2009-09-28 EP EP09778750.1A patent/EP2341927B1/en active Active
- 2009-09-28 WO PCT/EP2009/006980 patent/WO2010037514A2/en not_active Ceased
- 2009-09-28 UA UAA201103612A patent/UA103202C2/ru unknown
- 2009-09-28 DK DK16179169.4T patent/DK3132801T3/da active
- 2009-09-28 CA CA2739387A patent/CA2739387C/en active Active
- 2009-09-28 CA CA2936870A patent/CA2936870C/en active Active
- 2009-09-28 EP EP16179163.7A patent/EP3106175B1/en active Active
- 2009-09-28 NZ NZ624533A patent/NZ624533A/en not_active IP Right Cessation
- 2009-09-28 PT PT161792148T patent/PT3124043T/pt unknown
- 2009-09-28 UA UAA201103611A patent/UA110599C2/uk unknown
- 2009-09-28 LT LTEP16179174.4T patent/LT3120868T/lt unknown
- 2009-09-28 DK DK16179174.4T patent/DK3120868T3/da active
- 2009-09-28 LT LTEP16179192.6T patent/LT3120869T/lt unknown
- 2009-09-28 KR KR1020167022929A patent/KR101883426B1/ko active Active
- 2009-09-28 KR KR1020187021349A patent/KR102133402B1/ko not_active Expired - Fee Related
- 2009-09-28 TR TR2019/00852T patent/TR201900852T4/tr unknown
- 2009-09-28 BR BRPI0920759A patent/BRPI0920759A2/pt not_active Application Discontinuation
- 2009-09-28 RS RS20190118A patent/RS58443B1/sr unknown
- 2009-09-28 NZ NZ591882A patent/NZ591882A/xx not_active IP Right Cessation
- 2009-09-28 DK DK16179163.7T patent/DK3106175T3/da active
- 2009-09-28 RS RS20161160A patent/RS55531B1/sr unknown
- 2009-09-28 PT PT161791637T patent/PT3106175T/pt unknown
- 2009-09-28 TR TR2019/00809T patent/TR201900809T4/tr unknown
- 2009-09-28 ES ES16179192T patent/ES2819244T3/es active Active
- 2009-09-28 HU HUE16179241A patent/HUE042115T2/hu unknown
- 2009-09-28 HR HRP20201025TT patent/HRP20201025T8/hr unknown
- 2009-09-28 DK DK09778749.3T patent/DK2331118T5/da active
- 2009-09-28 DK DK16179226.2T patent/DK3120870T3/da active
- 2009-09-28 LT LTEP16179241.1T patent/LT3111952T/lt unknown
- 2009-09-28 DK DK16179192.6T patent/DK3120869T3/da active
- 2009-09-28 JP JP2011529472A patent/JP5855940B2/ja not_active Expired - Fee Related
- 2009-09-28 ES ES09778750.1T patent/ES2584245T3/es active Active
- 2009-09-28 PL PL16179214T patent/PL3124043T3/pl unknown
- 2009-09-28 PT PT161791926T patent/PT3120869T/pt unknown
- 2009-09-28 ES ES16179241T patent/ES2708654T3/es active Active
- 2009-09-28 HU HUE16179214A patent/HUE051030T2/hu unknown
- 2009-09-28 HU HUE16179169A patent/HUE047365T2/hu unknown
- 2009-09-28 PL PL16165070T patent/PL3069728T3/pl unknown
- 2009-09-28 CA CA2739384A patent/CA2739384C/en not_active Expired - Fee Related
- 2009-09-28 PT PT161792262T patent/PT3120870T/pt unknown
- 2009-10-01 US US12/571,602 patent/US8318677B2/en active Active
- 2009-10-01 US US12/571,776 patent/US8119139B2/en active Active
2012
- 2012-01-09 US US13/346,598 patent/US8961985B2/en active Active
- 2012-08-17 US US13/588,206 patent/US8653035B2/en active Active
2013
- 2013-03-15 US US13/841,013 patent/US8895514B2/en active Active
2014
- 2014-06-19 JP JP2014126001A patent/JP5883476B2/ja not_active Expired - Fee Related
- 2014-12-05 US US14/562,156 patent/US10227381B2/en active Active
2015
- 2015-02-12 CY CY20151100139T patent/CY1116302T1/el unknown
- 2015-02-26 HR HRP20150223TT patent/HRP20150223T8/hr unknown
- 2015-10-08 JP JP2015200021A patent/JP6150859B2/ja not_active Expired - Fee Related
2016
- 2016-02-05 JP JP2016021002A patent/JP6214066B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136519A patent/JP6297632B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136516A patent/JP2017029135A/ja active Pending
- 2016-07-11 JP JP2016136517A patent/JP6294913B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136518A patent/JP6294914B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136515A patent/JP6367266B2/ja not_active Expired - Fee Related
- 2016-08-02 US US15/226,038 patent/US10100085B2/en active Active
- 2016-08-02 US US15/226,161 patent/US10941181B2/en not_active Expired - Fee Related
- 2016-08-02 US US15/226,206 patent/US10047124B2/en active Active
- 2016-08-02 US US15/226,081 patent/US10046037B2/en active Active
- 2016-08-02 US US15/226,098 patent/US10906936B2/en not_active Expired - Fee Related
- 2016-08-02 US US15/226,126 patent/US10919931B2/en not_active Expired - Fee Related
- 2016-08-02 CY CY20161100759T patent/CY1119744T1/el unknown
- 2016-08-02 US US15/226,002 patent/US10047123B2/en active Active
- 2016-11-15 HR HRP20161504TT patent/HRP20161504T1/hr unknown
2017
- 2017-01-26 CY CY20171100124T patent/CY1118702T1/el unknown
- 2017-06-30 US US15/638,806 patent/US9993540B2/en active Active
2018
- 2018-09-19 US US16/136,008 patent/US20190010190A1/en not_active Abandoned
- 2018-12-18 HR HRP20182151TT patent/HRP20182151T1/hr unknown
- 2018-12-28 CY CY181101403T patent/CY1121098T1/el unknown
2019
- 2019-01-31 HR HRP20190202TT patent/HRP20190202T1/hr unknown
- 2019-02-12 CY CY20191100182T patent/CY1121258T1/el unknown
2020
- 2020-01-23 HR HRP20200110TT patent/HRP20200110T1/hr unknown
- 2020-01-28 CY CY20201100073T patent/CY1122677T1/el unknown
- 2020-05-05 HR HRP20200722TT patent/HRP20200722T1/hr unknown
- 2020-05-15 CY CY20201100449T patent/CY1122913T1/el unknown
- 2020-06-19 HR HRP20200988TT patent/HRP20200988T1/hr unknown
- 2020-06-26 CY CY20201100594T patent/CY1123089T1/el unknown
- 2020-06-26 HR HRP20201015TT patent/HRP20201015T8/hr unknown
- 2020-06-30 CY CY20201100606T patent/CY1123098T1/el unknown
- 2020-07-03 CY CY20201100613T patent/CY1123113T1/el unknown
- 2020-08-06 HR HRP20201228TT patent/HRP20201228T1/hr unknown
- 2020-10-19 CY CY20201100984T patent/CY1123526T1/el unknown
2021
- 2021-04-23 US US17/238,840 patent/US11136352B2/en active Active
- 2021-04-23 US US17/238,806 patent/US12221493B2/en active Active
- 2021-04-23 US US17/238,787 patent/US12234298B2/en active Active
- 2021-07-23 US US17/384,152 patent/US11208434B2/en not_active Expired - Fee Related
2025
- 2025-01-06 US US19/010,602 patent/US20260116918A1/en active Pending

Also Published As

Publication number	Publication date
EP3132801A1 (en)	2017-02-22
ES2584245T3 (es)	2016-09-26
RS60381B1 (sr)	2020-07-31
MX2011003540A (es)	2011-06-20
SI3111952T1 (sl)	2019-01-31
US20210253637A1 (en)	2021-08-19
PT3132801T (pt)	2020-02-04
CA2936869A1 (en)	2010-04-08
SI3069728T1 (sl)	2019-03-29
HRP20201015T8 (hr)	2022-01-21
PT2341927T (pt)	2016-08-02
EP2341927B1 (en)	2016-05-04
PL3120868T3 (pl)	2020-08-24
CA2936870A1 (en)	2010-04-08
US8961985B2 (en)	2015-02-24
RS53782B1 (sr)	2015-06-30
WO2010037513A1 (en)	2010-04-08
JP2012504563A (ja)	2012-02-23
DK3120869T3 (da)	2020-08-10
PL3132801T3 (pl)	2020-06-15
HRP20161504T1 (hr)	2016-12-30
SI2331118T1 (sl)	2017-01-31
ES2708654T3 (es)	2019-04-10
HRP20182151T1 (hr)	2019-02-08
US8318677B2 (en)	2012-11-27
CY1118702T1 (el)	2017-07-12
US20160376315A1 (en)	2016-12-29
CN102170900A (zh)	2011-08-31
CN106986919A (zh)	2017-07-28
BRPI0920791A2 (pt)	2019-12-10
AU2009300088B2 (en)	2014-09-04
EA023013B1 (ru)	2016-04-29
US20130004456A1 (en)	2013-01-03
PL2341927T3 (pl)	2016-11-30
CA2739384A1 (en)	2010-04-08
EP3111952A1 (en)	2017-01-04
US20130309193A1 (en)	2013-11-21
EP3069728B1 (en)	2018-11-14
KR20180088494A (ko)	2018-08-03
TR201900852T4 (tr)	2019-02-21
PL3106175T3 (pl)	2020-08-24
EP2331118B1 (en)	2016-10-26
HK1161106A1 (en)	2012-08-24
EP3120869B1 (en)	2020-07-22
HUE030296T2 (en)	2017-04-28
DK2172211T3 (en)	2015-02-16
PT3120869T (pt)	2020-09-22
US10100085B2 (en)	2018-10-16
US20110002963A1 (en)	2011-01-06
WO2010037514A3 (en)	2010-06-03
DK3111952T3 (en)	2019-01-28
JP2014239681A (ja)	2014-12-25
US20120141517A1 (en)	2012-06-07
RS55543B1 (sr)	2017-05-31
US20260116918A1 (en)	2026-04-30
EP2172211A1 (en)	2010-04-07
EP3120870B1 (en)	2020-04-01
JP5883476B2 (ja)	2016-03-15
CA2936868A1 (en)	2010-04-08
CN102170900B (zh)	2016-10-26
NZ603016A (en)	2014-05-30
CA2936868C (en)	2019-10-22
HUE049367T2 (hu)	2020-09-28
EP3111952B1 (en)	2018-10-31
JP2017000148A (ja)	2017-01-05
LT3120870T (lt)	2020-08-10
SI2172211T1 (sl)	2015-03-31
EP3120870A1 (en)	2017-01-25
ES2788129T8 (es)	2020-11-04
EP3069728A1 (en)	2016-09-21
EP3106175B1 (en)	2020-04-01
US20170326217A1 (en)	2017-11-16
PT3106175T (pt)	2020-07-01
CY1119744T1 (el)	2018-06-27
CY1123098T1 (el)	2021-10-29
CY1116302T1 (el)	2017-02-08
US10046037B2 (en)	2018-08-14
JP2017018102A (ja)	2017-01-26
DK3069728T3 (en)	2019-02-25
KR20220058655A (ko)	2022-05-09
US20210347822A1 (en)	2021-11-11
ES2819244T3 (es)	2021-04-15
DK3124043T3 (da)	2020-05-04
MX2011003539A (es)	2011-06-20
NZ591855A (en)	2012-11-30
RS60385B1 (sr)	2020-07-31
PL3111952T3 (pl)	2019-04-30
NZ591882A (en)	2012-12-21
SI3132801T1 (sl)	2020-03-31
US20150125478A1 (en)	2015-05-07
PT2331118T (pt)	2017-02-06
CN102170901A (zh)	2011-08-31
EP2172212B1 (en)	2016-10-05
TR201900809T4 (tr)	2019-02-21
DK2331118T5 (en)	2017-06-19
ES2802226T3 (es)	2021-01-18
PT3120870T (pt)	2020-07-01
RS60338B1 (sr)	2020-07-31
HUE050428T2 (hu)	2020-12-28
DK2341927T3 (en)	2016-08-15
CA2936924A1 (en)	2010-04-08
RS55531B1 (sr)	2017-05-31
RS60386B1 (sr)	2020-07-31
JP2012504393A (ja)	2012-02-23
WO2010037514A2 (en)	2010-04-08
NZ624533A (en)	2015-09-25
HRP20201015T1 (hr)	2020-10-16
EP2172212A2 (en)	2010-04-07
CY1122677T1 (el)	2021-03-12
HUE042115T2 (hu)	2019-06-28
US20100158931A1 (en)	2010-06-24
UA103202C2 (ru)	2013-09-25
CN102170901B (zh)	2015-01-07
HUE029360T2 (en)	2017-02-28
CA2739387C (en)	2019-10-29
US10906936B2 (en)	2021-02-02
CA2936870C (en)	2019-11-26
ES2536465T3 (es)	2015-05-25
JP6150859B2 (ja)	2017-06-21
EP3132801B1 (en)	2019-10-30
HRP20201228T1 (hr)	2021-02-05
HUE047365T2 (hu)	2020-04-28
EP2331118A1 (en)	2011-06-15
EP3120868A1 (en)	2017-01-25
DK3120870T3 (da)	2020-06-22
EP2172211B1 (en)	2014-12-03
US10227381B2 (en)	2019-03-12
KR101883426B1 (ko)	2018-07-31
HRP20160915T1 (hr)	2016-10-07
HRP20200722T1 (hr)	2020-10-16
EA201401104A1 (ru)	2015-05-29
US11136352B2 (en)	2021-10-05
HUE041446T2 (hu)	2019-05-28
CY1121258T1 (el)	2020-05-29
PT3111952T (pt)	2019-02-05
RS58443B1 (sr)	2019-04-30
KR20110074894A (ko)	2011-07-04
US10941181B2 (en)	2021-03-09
BRPI0920759A2 (pt)	2016-03-08
US9993540B2 (en)	2018-06-12
PL3069728T3 (pl)	2019-05-31
PL3120869T3 (pl)	2021-01-25
BRPI0920791B1 (pt)	2022-01-18
CY1122913T1 (el)	2021-10-29
JP2017023136A (ja)	2017-02-02
CY1121098T1 (el)	2019-12-11
US20160376316A1 (en)	2016-12-29
AU2009300088A1 (en)	2010-04-08
CA2936869C (en)	2019-08-06
LT3120869T (lt)	2020-11-10
SI3120868T1 (sl)	2020-08-31
US20190010190A1 (en)	2019-01-10
HUE031030T2 (en)	2017-06-28
JP6367266B2 (ja)	2018-08-01
LT3120868T (lt)	2020-08-10
PT2172212T (pt)	2016-12-22
CA2936920A1 (en)	2010-04-08
PL3120870T3 (pl)	2020-07-27
KR101687840B1 (ko)	2016-12-19
LT3069728T (lt)	2019-02-11
HRP20200988T1 (hr)	2020-10-16
CA2936887C (en)	2019-11-12
KR20200085381A (ko)	2020-07-14
CA2936982A1 (en)	2010-04-08
EA023378B1 (ru)	2016-05-31
EA201100587A1 (ru)	2011-10-31
RS60006B1 (sr)	2020-04-30
RS60656B1 (sr)	2020-09-30
EA032437B1 (ru)	2019-05-31
CA2936887A1 (en)	2010-04-08
EP3124043B1 (en)	2020-04-29
BRPI0920791B8 (pt)	2022-02-15
CA2739387A1 (en)	2010-04-08
JP2016047825A (ja)	2016-04-07
ES2788129T3 (es)	2020-10-20
HRP20201025T1 (hr)	2020-12-25
US20210238227A1 (en)	2021-08-05
EP3124043A1 (en)	2017-02-01
JP5855940B2 (ja)	2016-02-09
HUE051030T2 (hu)	2021-01-28
HRP20150223T1 (hr)	2015-06-05
DK3132801T3 (da)	2020-02-10
SI2172212T1 (sl)	2016-12-30
UA110599C2 (uk)	2016-01-25
US12234298B2 (en)	2025-02-25
US20160376313A1 (en)	2016-12-29
ES2804723T3 (es)	2021-02-09
LT2172212T (lt)	2016-11-10
EP2341927A2 (en)	2011-07-13
SI3120869T1 (sl)	2020-10-30
DK2172212T3 (da)	2016-12-19
HRP20190202T1 (hr)	2019-03-22
CY1123526T1 (el)	2022-03-24
LT3124043T (lt)	2020-07-10
US20160376312A1 (en)	2016-12-29
JP2017029135A (ja)	2017-02-09
US10919931B2 (en)	2021-02-16
US11208434B2 (en)	2021-12-28
HRP20150223T8 (hr)	2015-07-03
JP2016145210A (ja)	2016-08-12
EP3106175A1 (en)	2016-12-21
LT3132801T (lt)	2020-02-10
CA2936920C (en)	2019-12-03
US10047123B2 (en)	2018-08-14
DK3106175T3 (da)	2020-06-22
PT3069728T (pt)	2019-02-13
US10047124B2 (en)	2018-08-14
HUE049364T2 (hu)	2020-09-28
US12221493B2 (en)	2025-02-11
SI3120870T1 (sl)	2020-08-31
LT3111952T (lt)	2018-12-27
HRP20200110T1 (hr)	2020-05-15
HRP20201025T8 (hr)	2022-01-07
SI3106175T1 (sl)	2020-08-31
AU2009300087A1 (en)	2010-04-08
CY1123113T1 (el)	2021-10-29
CA2739384C (en)	2017-05-02
JP5753783B2 (ja)	2015-07-22
EP3120868B1 (en)	2020-04-08
HK1159526A1 (zh)	2012-08-03
ES2802227T3 (es)	2021-01-18
JP2017018101A (ja)	2017-01-26
US8653035B2 (en)	2014-02-18
AU2009300087B2 (en)	2014-09-04
ES2770090T3 (es)	2020-06-30
JP6294914B2 (ja)	2018-03-14
CA2936924C (en)	2019-07-16
SI2341927T1 (sl)	2016-08-31
UA125277C2 (uk)	2022-02-16
PL2172212T3 (pl)	2017-04-28
PT2172211E (pt)	2015-03-09
PT3124043T (pt)	2020-05-12
CA2936982C (en)	2019-12-03
PL3124043T3 (pl)	2020-07-27
US20160376314A1 (en)	2016-12-29
EP2172212A3 (en)	2010-04-14
US20160376317A1 (en)	2016-12-29
JP6294913B2 (ja)	2018-03-14
RS58229B1 (sr)	2019-03-29
HUE049366T2 (hu)	2020-09-28
MX338294B (es)	2016-04-11
US8119139B2 (en)	2012-02-21
US8895514B2 (en)	2014-11-25
ES2710608T3 (es)	2019-04-26
LT3106175T (lt)	2020-08-10
JP6214066B2 (ja)	2017-10-18
PL2172211T3 (pl)	2015-05-29
KR20160103558A (ko)	2016-09-01
KR20110082155A (ko)	2011-07-18
SI3124043T1 (sl)	2020-07-31
EP3120869A1 (en)	2017-01-25
PT3120868T (pt)	2020-07-16
RS55043B1 (sr)	2016-12-30
EA201100586A1 (ru)	2011-10-31
KR102392070B1 (ko)	2022-04-29
PL2331118T3 (pl)	2017-05-31
LT2331118T (lt)	2016-12-27
DK3120868T3 (da)	2020-06-22
US20210261614A1 (en)	2021-08-26
DK2331118T3 (da)	2017-01-09
US20160355550A1 (en)	2016-12-08
KR101756488B1 (ko)	2017-07-11
ES2612466T3 (es)	2017-05-17
ES2607460T3 (es)	2017-03-31
CY1123089T1 (el)	2021-10-29
JP6297632B2 (ja)	2018-03-20
KR102133402B1 (ko)	2020-07-14

Publication	Publication Date	Title
HRP20170115T1 (hr)	2017-03-24	Sastav tumoru-pridruženih peptida i povezanog cjepiva protiv karcinoma za liječenje glioblastoma (gbm-a) i drugih karcinoma
JP2012504563A5 (2)	2013-06-20
Yi et al.	2023	Vaccine-like nanomedicine for cancer immunotherapy
JP2013522276A5 (2)	2013-10-17
JP2010534627A5 (2)	2011-11-17
EP2111867B1 (en)	2011-10-05	Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
ES2365077T3 (es)	2011-09-21	Péptido antígeno anticáncer derivado de sparc y composición farmacéutica que comprende el mismo.
JP2018522822A5 (2)	2019-06-20
JP2013536157A5 (2)	2014-07-17
MX2020011672A (es)	2020-12-03	Peptidos novedosos y acidos nucleicos de los mismos contra tumores tal como los de cancer gastrico y gastrointestinal.
Hwang et al.	2009	Endoscopic resection for the treatment of gastric subepithelial tumors originated from the muscularis propria layer
JP2012021028A5 (2)	2012-05-17
WO2012117257A8 (en)	2013-09-19	Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer
WO2016035808A1 (ja)	2016-03-10	ビスホスホネート剤を含む細胞性免疫用ワクチン医薬組成物
HRP20200734T1 (hr)	2020-09-18	Derivat klorina koristan u fotodinamičkoj terapiji i dijagnozi
ES2992031T3 (es)	2024-12-05	Péptidos de arginasa inmunógenos
RU2020106891A (ru)	2021-08-16	Применение нейрегулина для лечения повреждения периферических нервов
WO2012151272A3 (en)	2012-12-27	T-cell vaccination with viral vectors via mechanical epidermal disruption
JP2013506626A5 (2)	2013-11-21
Tarasov et al.	1999	Combined surgical and immunotherapeutic treatment of patients with fourth stage colon cancer
CU23297A1 (es)	2008-07-24	Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
ES2399218T3 (es)	2013-03-26	Saponinas inmunoestimulantes para usar en terapia de destrucción tumoral in situ
RU2530523C2 (ru)	2014-10-10	Способ противоопухолевой иммунотерапии
Zangeneh et al.	2024	Preparation and Formulation of a New Therapeutic Supplement by the Combination of Dendritic Cells and IPI-549 (Eganelisib) for the Treatment of Breast Cancer in BALB/c Mice
Aravindaram et al.	2009	AKMG Muhammad, Marienela Candolfi, Kader Yagiz, David Foulad, Maxim Khayznikov, Chunyan Liu, Kurt Kroeger, Pedro R. Lowenstein, Maria G. Castro. 1Gene Therapeutics Research Institute, DAVIS 5090, Cedars-Sinai Medical Center, Los Angeles, CA.